The Persistent Corneal Epithelial Defects Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Persistent Corneal Epithelial Defects Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Persistent Corneal Epithelial Defects Market.
Some of the key takeaways from the Persistent Corneal Epithelial Defects Pipeline Report:
- Companies across the globe are diligently working toward developing novel Persistent Corneal Epithelial Defects treatment therapies with a considerable amount of success over the years.
- Persistent Corneal Epithelial Defects companies working in the treatment market are Kiora Pharmaceuticals, Inc., Xequel Bio, Kala Pharmaceuticals, Amber Ophthalmics, OcuNexus Therapeutics, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases/Mimetech, and others, are developing therapies for the Persistent Corneal Epithelial Defects treatment
- Emerging Persistent Corneal Epithelial Defects therapies in the different phases of clinical trials are- KIO-201, iNexin, KPI-012, Nexagon, Nexagon, ST266, RGN-259, REC-0559, and others are expected to have a significant impact on the Persistent Corneal Epithelial Defects market in the coming years.
- In August 2023, The AMB-01-006 (NEXPEDE-1) trial has enrolled its first participant, according to Amber Ophthalmics Inc. The NEXPEDE-1 study (NCT05966493) compares two concentrations of lufepirsen ophthalmic gel (Nexagon) for the treatment of persistent corneal epithelial defects (PCED) in a randomly assigned, double-masked, vehicle-controlled Phase 2/3 clinical trial
- In June 2020, To evaluate the effectiveness and safety of Nexagon® (NEXAGON) given topically in participants with corneal persistent epithelial defects resulting from severe ocular chemical and/or thermal injuries, Amber Ophthalmics, Inc. started a Phase II randomised, prospective, double-masked, vehicle-controlled trial.
Persistent Corneal Epithelial Defects Overview
Through tight connections between adjacent cells, the multi-layered corneal epithelium serves as a barrier against infectious pathogens, and it continuously renews cells in the basal cell layer to preserve its smooth optical surface. The failure of fast re-epithelialization and closure within 10–14 days following a corneal injury, even with routine supportive therapy, results in persistent corneal epithelial defects (PEDs or PCEDs).
Get a Free Sample PDF Report to know more about Persistent Corneal Epithelial Defects Pipeline Therapeutic Assessment-
Emerging Persistent Corneal Epithelial Defects Drugs Under Different Phases of Clinical Development Include:
- KIO-201: Kiora Pharmaceuticals, Inc.
- iNexin: Xequel Bio
- KPI-012: Kala Pharmaceuticals
- Nexagon: Amber Ophthalmics
- Nexagon: OcuNexus Therapeutics
- ST266: Noveome Biotherapeutics
- RGN-259: RegeneRx Biopharmaceuticals
- REC-0559: Recordati Rare Diseases/Mimetech
Persistent Corneal Epithelial Defects Route of Administration
Persistent Corneal Epithelial Defects pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Persistent Corneal Epithelial Defects Molecule Type
Persistent Corneal Epithelial Defects Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Persistent Corneal Epithelial Defects Pipeline Therapeutics Assessment
- Persistent Corneal Epithelial Defects Assessment by Product Type
- Persistent Corneal Epithelial Defects By Stage and Product Type
- Persistent Corneal Epithelial Defects Assessment by Route of Administration
- Persistent Corneal Epithelial Defects By Stage and Route of Administration
- Persistent Corneal Epithelial Defects Assessment by Molecule Type
- Persistent Corneal Epithelial Defects by Stage and Molecule Type
DelveInsight's Persistent Corneal Epithelial Defects Report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Persistent Corneal Epithelial Defects product details are provided in the report. Download the Persistent Corneal Epithelial Defects pipeline report to learn more about the emerging Persistent Corneal Epithelial Defects therapies
Some of the key companies in the Persistent Corneal Epithelial Defects Therapeutics Market include:
Key companies developing therapies for Persistent Corneal Epithelial Defects are - OcuNexus Therapeutics, Eyevance Pharmaceuticals, and Noveome Biotherapeutics, and others.
Persistent Corneal Epithelial Defects Pipeline Analysis:
The Persistent Corneal Epithelial Defects pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Persistent Corneal Epithelial Defects with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Persistent Corneal Epithelial Defects Treatment.
- Persistent Corneal Epithelial Defects key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Persistent Corneal Epithelial Defects Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Persistent Corneal Epithelial Defects market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Persistent Corneal Epithelial Defects drugs and therapies
Persistent Corneal Epithelial Defects Pipeline Market Drivers
- Increasing Research and Development Activities, advancements in Understanding of Disease are some of the important factors that are fueling the Persistent Corneal Epithelial Defects Market.
Persistent Corneal Epithelial Defects Pipeline Market Barriers
- However, lack of Universal Guidelines regarding disease diagnosis and treatment, adverse Effects in the current treatment options and other factors are creating obstacles in the Persistent Corneal Epithelial Defects Market growth.
Scope of Persistent Corneal Epithelial Defects Pipeline Drug Insight
- Coverage: Global
- Key Persistent Corneal Epithelial Defects Companies: Kiora Pharmaceuticals, Inc., Xequel Bio, Kala Pharmaceuticals, Amber Ophthalmics, OcuNexus Therapeutics, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases/Mimetech, and others
- Key Persistent Corneal Epithelial Defects Therapies: KIO-201, iNexin, KPI-012, Nexagon, Nexagon, ST266, RGN-259, REC-0559, and others
- Persistent Corneal Epithelial Defects Therapeutic Assessment: Persistent Corneal Epithelial Defects current marketed and Persistent Corneal Epithelial Defects emerging therapies
- Persistent Corneal Epithelial Defects Market Dynamics: Persistent Corneal Epithelial Defects market drivers and Persistent Corneal Epithelial Defects market barriers
Request for Sample PDF Report for Persistent Corneal Epithelial Defects Pipeline Assessment and clinical trials
Table of Contents
1. Persistent Corneal Epithelial Defects Report Introduction
2. Persistent Corneal Epithelial Defects Executive Summary
3. Persistent Corneal Epithelial Defects Overview
4. Persistent Corneal Epithelial Defects- Analytical Perspective In-depth Commercial Assessment
5. Persistent Corneal Epithelial Defects Pipeline Therapeutics
6. Persistent Corneal Epithelial Defects Late Stage Products (Phase II/III)
7. Persistent Corneal Epithelial Defects Mid Stage Products (Phase II)
8. Persistent Corneal Epithelial Defects Early Stage Products (Phase I)
9. Persistent Corneal Epithelial Defects Preclinical Stage Products
10. Persistent Corneal Epithelial Defects Therapeutics Assessment
11. Persistent Corneal Epithelial Defects Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Persistent Corneal Epithelial Defects Key Companies
14. Persistent Corneal Epithelial Defects Key Products
15. Persistent Corneal Epithelial Defects Unmet Needs
16 . Persistent Corneal Epithelial Defects Market Drivers and Barriers
17. Persistent Corneal Epithelial Defects Future Perspectives and Conclusion
18. Persistent Corneal Epithelial Defects Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
